ClotTriever System for Mechanical Thrombectomy of Deep Vein Thrombosis

Abstract

There is increasing evidence that early and comprehensive removal of thrombus in deep vein thrombosis is associated with improved outcomes, including decreased incidence of post-thrombotic syndrome and debilitating long-term symptoms. Catheter-directed thrombolysis is effective for the rapid removal of clot, but it is associated with high bleeding risk. Percutaneous mechanical thrombectomy is a highly effective method for the removal of clot without the use of systemic or catheter-directed thrombolytic therapy. The Inari ClotTriever system (Inari Medical Inc., CA, USA) is a thrombectomy device, which is approved for deep vein thrombosis by the US FDA in 2017. Herein we review the current treatment strategies using the ClotTriever system, its specifications, indications and current state of literature.

Plain language summary

Deep venous thrombosis is a common disease that causes blood clots in the veins. Complete removal of clot is associated with better outcomes, including decreased incidence of post-thrombotic syndrome (symptoms including leg heaviness, pain, cramping, swelling and discomfort). The ClotTriever system (Inari Medical, Inc., CA, USA) is a device approved for the removal of clot in veins without using clot-busting medications that increase bleeding risk. This review describes the types of devices, indications and current research.

Tweetable abstract

@shinmeichan, @fabianmaxlg and Dr. Mojibian from @Yale_IR discuss the uses and current research endeavors regarding the Inari ClotTriever system for mechanical thrombectomy of deep vein thrombosis.

Keywords:

• catheter directed thrombolysis
• chronic deep vein thrombosis
• ClotTriever
• deep vein thrombosis
• thrombectomy

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at:www.tandfonline.com/doi/full/10.2217/fca-2022-0100

Acknowledgments

The authors thank S Vandrangi, PhD (Inari Medical Inc.), for providing technical information and illustrations.

Financial & competing interests disclosure

HM is a consultant for Inari Medical, Inc. and a shareholder of Alyka Health. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.